34P - Prognostic impact of disseminated tumor cell in breast cancer patients: 10 year follow up results
|Date||08 May 2014|
|Session||Welcome reception and Poster Walk|
|Topics|| Breast Cancer
|Presenter||Ku Sang Kim|
|Citation||Annals of Oncology (2014) 25 (suppl_1): i8-i16. 10.1093/annonc/mdu066|
Breast cancer survival rates are greatly influenced by distant metastasis. In breast cancer cytokeratin 19 (CK19) is the most commonly used marker for detection of tumor cells disseminated in the lymph nodes, peripheral blood, and bone marrow. We previously reported that the presence of bone marrow CK19 has a correlation with distant disease-free survival (DDFS), and applied this as a predictive clinical value in both DDFS and overall survival (OS) in a 10-year follow-up.
Materials and methods:
From 1999 to 2003, 254 breast cancer patients underwent bone marrow aspirations intra-operatively to detect CK19 by nested reverse transcriptase polymerase chain reaction (nRT-PCR). The correlation between the clinical features and the presence of bone marrow CK19 was reviewed and analyzed using 10-year follow-up data on distant recurrence and survival.
63 (26.2%) patients were in the CK19 positive group and 177 (73.8%) patients were in the CK19 negative group. The DDFS rates in the CK19 positive group and CK19 negative group at the 10-year follow-up were 68.3% (43/63) and 86.4% (153/177), respectively (HR 2.69, 95%CI: 1.49–4.88, p = 0.001). For OS rates, 68.3% (43/63) of the CK19 positive group and 83.6% (148/177) of the CK19 negative group survived (HR 2.16, 95%CI: 1.23–3.83, p = 0.008). Analyzing survival rates by bone marrow CK19 status at each stage, only in stage II patients did we see significantly lower DDFS (61.3% vs. 92.3%, p = 0.0002) and OS (67.7% vs. 91.0%, p = 0.001) rates in the CK19 positive group compared with the CK 19 negative group.
The presence of bone marrow CK19 has been shown in the 10-year study to lead to unfavorable outcomes in DDFS and OS rates. Therefore, CK19 could be a useful predictive marker for the distant metastasis of breast cancer, especially in stage II.
All authors have declared no conflicts of interest.